Oragenics (OGEN) Short-Term Debt issuances (2010 - 2026)
Oragenics' (OGEN) quarterly Short-Term Debt issuances came in at $171214.0 in Q1 2026, down 12.45% YoY from $195565.0 in Q1 2025, and down 94.29% on a QoQ basis from $3.0 million in Q3 2025.
Oragenics (OGEN) Short-Term Debt issuances (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Short-Term Debt issuances data on file, last reported at $171214.0 in Q1 2026.
- Quarterly Short-Term Debt issuances fell 12.45% year-over-year to $171214.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 370.14% YoY) and the FY2025 annual result came in at $3.3 million, up 380.23% from the prior year.
- Short-Term Debt issuances retreated to $171214.0 in Q1 2026, from $3.0 million in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $3.0 million in Q3 2025 to a low of $103505.0 in Q3 2022.
- A 5-year average of $332693.9 and a median of $158517.0 in 2022 frame the typical range for Short-Term Debt issuances.
- Annual changes were most pronounced in 2025 — Short-Term Debt issuances jumped 2451.45% — and 2026, when it decreased 12.45%.
- Tracing OGEN's Short-Term Debt issuances over 5 years: stood at $157284.0 in 2022, then increased by 14.9% to $180717.0 in 2023, then surged by 45.44% to $262826.0 in 2024, then surged by 1041.44% to $3.0 million in 2025, then plunged by 94.29% to $171214.0 in 2026.
- The last three Short-Term Debt issuances figures came in at $171214.0 (Q1 2026), $3.0 million (Q3 2025), and $132963.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | 56,134.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56,134.00 |
| Jun 30, 2026 | 56,134.00 |
| Mar 31, 2026 | 171,214.00 |
| Mar 31, 2026 | 171,214.00 |
| Sep 30, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 132,963.00 |
| Jun 30, 2025 | 132,963.00 |
| Mar 31, 2025 | 195,565.00 |
| Mar 31, 2025 | 195,565.00 |
| Dec 31, 2024 | 262,826.00 |
| Dec 31, 2024 | 262,826.00 |
| Sep 30, 2024 | 117,580.00 |
| Sep 30, 2024 | 117,580.00 |
| Jun 30, 2024 | 126,840.00 |
| Jun 30, 2024 | 126,840.00 |
| Mar 31, 2024 | 185,863.00 |
| Mar 31, 2024 | 185,863.00 |
| Dec 31, 2023 | 180,717.00 |
| Dec 31, 2023 | 180,717.00 |